Form 4: Kenvue Inc. Executive Caroline Tillett Reports Acquisition of Stock Options and Restricted Stock Units

Caroline Tillett, Chief Scientific Officer of Kenvue Inc., reports the acquisition of stock options and restricted stock units in a recent SEC filing.

Summary

• Caroline Tillett, Chief Scientific Officer of Kenvue Inc. (KVUE), filed a Form 4 with the SEC on March 7, 2024.
• The filing reports a transaction date of March 5, 2024.
• Tillett acquired 111,009 stock options with an exercise price of $19.01, exercisable from March 5, 2024, and expiring on March 5, 2034.
• She also acquired 12,340 restricted stock units (RSUs), which correspond 1-for-1 with Kenvue's common stock.
• These RSUs vest in three equal installments on March 5, 2025, March 5, 2026, and March 5, 2027, contingent upon continued service.
• Following the reported transactions, Tillett directly owns 111,009 stock options and 12,340 restricted stock units.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The acquisition of stock options and RSUs can be seen as a positive sign of the executive's commitment, but it's a routine event.

Positives

• The acquisition of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule of the RSUs incentivizes continued service and commitment to the company.

Future Outlook

The vesting schedule of the RSUs suggests a long-term commitment from the executive to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that the Chief Scientific Officer is incentivized to contribute to the long-term success of Kenvue.

Stakeholder Impact

• Shareholders may view the acquisition of stock options and RSUs by the Chief Scientific Officer as a positive sign, aligning her interests with theirs.
• Employees may see this as a sign of confidence in the company's future.

Key Dates